Document is current
Any future updates will be listed below
-
Authors
Schwartz, Carolyn E. https://orcid.org/0000-0002-9173-7774
Stark, Roland B.
Borowiec, Katrina
Myren, Karl-Johan
-
Funding
Funding for this research was provided by:
Alexion Pharmaceuticals
- License Information
-
More Information
Article History
Received: 7 June 2021
Accepted: 13 September 2021
First Online: 28 September 2021
Declarations
:
: The trial was conducted in accordance with the provision of the Declaration of Helsinki, the International Conference on Harmonization guidelines for Good Clinical Practice, and applicable regulatory requirements. The trial was approved by the institutional review board at each participating institution. All the patients provided written informed consent before participation. For the EORTC general-population data, ethical approval was not sought as this study was solely based on panel research data collected by GfK SE. The survey conformed to the required ethical standards by obtaining written informed consent from all participants and collecting data completely anonymously. All participants provided informed consent prior to beginning the survey.
: All participants provided permission in the informed consent for their aggregated data being used in research publications.
: Dr. Schwartz and Mr. Stark are employees of and Ms. Borowiec an independent contractor of DeltaQuest Foundation, which received research funding for the work reported herein. Mr. Myren is an employee of Alexion Pharmaceuticals which developed the drugs being evaluated.
